Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care successfully places senior notes
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Bond
Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care
successfully places senior notes
18.01.2012 / 16:49
---------------------------------------------------------------------
Contact: Fresenius Medical Care AG & Co. KGaA
Oliver Maier Else-Kröner-Str.1
Phone: + 49 6172 609 2601 61352 Bad Homburg
Fax: + 49 6172 609 2301 Germany
www.fmc-ag.com
North America:
Terry L. Morris
Phone: + 1 800 948 2538
Fax: + 1 615 345 5605
E-mail: ir@fmc-ag.com January 18, 2012
Investor News
Fresenius Medical Care successfully places senior notes
Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA (the 'company'
or 'Fresenius Medical Care'; Frankfurt Stock Exchange: FME / New York Stock
Exchange: FMS), the world's largest provider of dialysis products and
services, successfully placed three tranches of U.S. dollar and
euro-denominated senior unsecured notes (together the 'senior notes').
Proceeds amounting to approximately $1.82 billion are intended to be used
for acquisitions, including the acquisition of Liberty Dialysis Holdings,
Inc., to refinance indebtedness and for general corporate purposes.
The coupon for the dollar-denominated senior notes in the principal amount
of $800 million due 2019 will be 5.625% and the coupon for the
dollar-denominated senior notes in the principal amount of $700 million due
2022 will be 5.875%. The coupon for the euro-denominated senior notes in
the principal amount of EUR250 million due 2019 will be 5.25%. All tranches
were issued at par.
Michael Brosnan, chief financial officer of the company, commented: 'This
is the largest placement of senior notes in the history of Fresenius
Medical Care and an important step in the financing of our growth strategy.
We are very pleased to have successfully completed this offering at
favorable rates in an overall challenging market environment. We believe
this demonstrates that investors continue to recognize our financial
stability and sustainable financial strength.'
The dollar-denominated senior notes were offered by Fresenius Medical Care
US Finance II, Inc. and the euro-denominated senior notes were offered by
FMC Finance VIII S.A. Both issuers are wholly-owned subsidiaries of the
company. The senior notes were offered through a private placement to
institutional investors and will be guaranteed jointly and severally by the
company and its subsidiaries, Fresenius Medical Care Holdings, Inc. and
Fresenius Medical Care Deutschland GmbH.
The senior notes have not been registered under the Securities Act of 1933
as amended, but were offered to 'qualified institutional buyers' (QIBs) in
the U.S. pursuant to the exemption from registration provided by Rule 144A
under the Securities Act and in exempted 'offshore transactions' pursuant
to Regulation S under the Securities Act. The senior notes may not be
offered or sold in the U.S. unless registered under the Securities Act or
pursuant to an applicable exemption from registration requirements.
Application has been made for admission of the senior notes to trading on
the regulated market of the Luxembourg Stock Exchange.
***************
About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2 million
individuals worldwide. Through its network of 2,874 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatment to 228,239 patients around the
globe. Fresenius Medical Care is also the world's leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products.
Disclaimer
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
The information contained in this release may not be issued or distributed
in or into Canada, Australia or Japan and does not constitute an offer to
sell nor an invitation to subscribe for, underwrite or otherwise acquire
securities in Canada, Australia or Japan.
This release does not constitute or form part of, and should not be
construed as, an offer or invitation to subscribe for, underwrite or
otherwise acquire, any securities of FMC Finance VIII S.A., or Fresenius
Medical Care US Finance II, Inc. or Fresenius Medical Care or any present
or future member of its group nor should it or any part of it form the
basis of, or be relied on in connection with, any contract to purchase or
subscribe for any securities of FMC Finance VIII S.A. or Fresenius Medical
Care US Finance II, Inc. or Fresenius Medical Care or any member of its
group. In particular, this release is not an offer to sell or a
solicitation of offers to purchase any securities in the United States of
America (including its territories and possessions), and securities of FMC
Finance VIII S.A. and Fresenius Medical Care US Finance II, Inc. and
Fresenius Medical Care may not be offered or sold in the United States of
America or to United States persons absent registration under the
Securities Act of 1933, as amended, or pursuant to an applicable exemption
from registration.
End of Corporate News
---------------------------------------------------------------------
18.01.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.fmc-ag.de
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart; Terminbörse EUREX; NYSE
End of News DGAP News-Service
---------------------------------------------------------------------
153285 18.01.2012
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Bond
Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care
successfully places senior notes
18.01.2012 / 16:49
---------------------------------------------------------------------
Contact: Fresenius Medical Care AG & Co. KGaA
Oliver Maier Else-Kröner-Str.1
Phone: + 49 6172 609 2601 61352 Bad Homburg
Fax: + 49 6172 609 2301 Germany
www.fmc-ag.com
North America:
Terry L. Morris
Phone: + 1 800 948 2538
Fax: + 1 615 345 5605
E-mail: ir@fmc-ag.com January 18, 2012
Investor News
Fresenius Medical Care successfully places senior notes
Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA (the 'company'
or 'Fresenius Medical Care'; Frankfurt Stock Exchange: FME / New York Stock
Exchange: FMS), the world's largest provider of dialysis products and
services, successfully placed three tranches of U.S. dollar and
euro-denominated senior unsecured notes (together the 'senior notes').
Proceeds amounting to approximately $1.82 billion are intended to be used
for acquisitions, including the acquisition of Liberty Dialysis Holdings,
Inc., to refinance indebtedness and for general corporate purposes.
The coupon for the dollar-denominated senior notes in the principal amount
of $800 million due 2019 will be 5.625% and the coupon for the
dollar-denominated senior notes in the principal amount of $700 million due
2022 will be 5.875%. The coupon for the euro-denominated senior notes in
the principal amount of EUR250 million due 2019 will be 5.25%. All tranches
were issued at par.
Michael Brosnan, chief financial officer of the company, commented: 'This
is the largest placement of senior notes in the history of Fresenius
Medical Care and an important step in the financing of our growth strategy.
We are very pleased to have successfully completed this offering at
favorable rates in an overall challenging market environment. We believe
this demonstrates that investors continue to recognize our financial
stability and sustainable financial strength.'
The dollar-denominated senior notes were offered by Fresenius Medical Care
US Finance II, Inc. and the euro-denominated senior notes were offered by
FMC Finance VIII S.A. Both issuers are wholly-owned subsidiaries of the
company. The senior notes were offered through a private placement to
institutional investors and will be guaranteed jointly and severally by the
company and its subsidiaries, Fresenius Medical Care Holdings, Inc. and
Fresenius Medical Care Deutschland GmbH.
The senior notes have not been registered under the Securities Act of 1933
as amended, but were offered to 'qualified institutional buyers' (QIBs) in
the U.S. pursuant to the exemption from registration provided by Rule 144A
under the Securities Act and in exempted 'offshore transactions' pursuant
to Regulation S under the Securities Act. The senior notes may not be
offered or sold in the U.S. unless registered under the Securities Act or
pursuant to an applicable exemption from registration requirements.
Application has been made for admission of the senior notes to trading on
the regulated market of the Luxembourg Stock Exchange.
***************
About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2 million
individuals worldwide. Through its network of 2,874 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatment to 228,239 patients around the
globe. Fresenius Medical Care is also the world's leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products.
Disclaimer
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
The information contained in this release may not be issued or distributed
in or into Canada, Australia or Japan and does not constitute an offer to
sell nor an invitation to subscribe for, underwrite or otherwise acquire
securities in Canada, Australia or Japan.
This release does not constitute or form part of, and should not be
construed as, an offer or invitation to subscribe for, underwrite or
otherwise acquire, any securities of FMC Finance VIII S.A., or Fresenius
Medical Care US Finance II, Inc. or Fresenius Medical Care or any present
or future member of its group nor should it or any part of it form the
basis of, or be relied on in connection with, any contract to purchase or
subscribe for any securities of FMC Finance VIII S.A. or Fresenius Medical
Care US Finance II, Inc. or Fresenius Medical Care or any member of its
group. In particular, this release is not an offer to sell or a
solicitation of offers to purchase any securities in the United States of
America (including its territories and possessions), and securities of FMC
Finance VIII S.A. and Fresenius Medical Care US Finance II, Inc. and
Fresenius Medical Care may not be offered or sold in the United States of
America or to United States persons absent registration under the
Securities Act of 1933, as amended, or pursuant to an applicable exemption
from registration.
End of Corporate News
---------------------------------------------------------------------
18.01.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.fmc-ag.de
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart; Terminbörse EUREX; NYSE
End of News DGAP News-Service
---------------------------------------------------------------------
153285 18.01.2012